

# Acetylation of MEK2 and I $\kappa$ B kinase (IKK) activation loop residues by YopJ inhibits signaling

Rohit Mittal<sup>†‡§</sup>, Sew-Yeu Peak-Chew<sup>†</sup>, and Harvey T. McMahon<sup>†</sup>

<sup>†</sup>Medical Research Council Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, United Kingdom; and <sup>‡</sup>Department of Biological Sciences, Tata Institute of Fundamental Research, Mumbai 400005, India

Communicated by Richard Henderson, Medical Research Council, Cambridge, United Kingdom, October 13, 2006 (received for review September 15, 2006)

To overcome host defenses, bacterial pathogens of the genus *Yersinia* inject specific effector proteins into colonized mammalian cells. One such virulence factor, YopJ, inhibits the host inflammatory response and induces apoptosis of immune cells by blocking multiple signaling pathways, including the MAPK and NF- $\kappa$ B pathways. In this study, we show that YopJ exerts its deleterious effects by catalyzing the acetylation of two serine residues in the activation loop of the MAP kinase kinase, MEK2. This covalent modification prevents the phosphorylation of these serine residues that is required for activation of MEK2 and downstream signal propagation. We also show that YopJ causes acetylation of a threonine residue in the activation loop of both the  $\alpha$  and  $\beta$  subunits of the NF- $\kappa$ B pathway kinase, IKK. These results establish a hitherto uncharacterized mode of action for bacterial toxins and suggest the possibility that serine/threonine acetylation may occur even under nonpathogenic conditions and may be a widespread protein modification regulating protein function in eukaryotic cells.

inflammation | MEK

Understanding the mode of action of bacterial toxins has provided insight into the working of mammalian cells especially with regard to signal transduction pathways that impinge upon the activation of the innate immune system (1, 2). Historically, plague has been one of the most devastating diseases to humans, second only to smallpox. The bacillus *Yersinia pestis* is the causative agent of plague, and two other *Yersinia* species, *Yersinia pseudotuberculosis* and *Yersinia enterocolitica*, cause septicemic and gastrointestinal disorders (3). These pathogens inject a bouquet of six effector proteins into the mammalian cell cytosol using a type III secretion apparatus (4). These *Yersinia* outer proteins (Yops) help the pathogen multiply extracellularly in the host by preventing its phagocytosis and by slowing down the onset of the inflammatory response (5). YopE, YopT, and YopO target the Rho family of GTP-binding proteins that control actin cytoskeleton dynamics whereas YopH dephosphorylates focal adhesion proteins, thus inhibiting focal adhesion disassembly. Together, the action of these Yops contributes to the resistance of *Yersinia* to undergo phagocytosis, a process known to require remodeling of the actin cytoskeleton and of focal adhesions. Suppression of phagocytosis enables *Yersinia* to evade the macrophage defense network, thereby allowing them to proliferate in Peyer's patches as extracellular microcolonies. The leucine-rich protein, YopM, has been shown to bind to several host cell kinases, resulting in their activation (6). The remaining outer protein, YopJ (also called YopP in *Y. enterocolitica*) has emerged as an important agent that leads to the reduced host inflammatory response characteristic of *Yersinia* infections (5). Exposure of macrophages to lipopolysaccharide leads to the activation of NF- $\kappa$ B and of several members of the MAPK family that promote the production of proinflammatory cytokines such as TNF- $\alpha$ . YopJ induces apoptosis in macrophages (7), and it was shown that inhibition of both MAPK and NF- $\kappa$ B pathways was necessary for this effect (8), suggesting that *Yersinia* might neutralize and eliminate macrophages without

inducing an inflammatory response. Suppression of the inflammatory response is mediated in part by the inhibition of the transcription factor NF- $\kappa$ B, the activation of which is central to the onset of inflammation. YopJ has been shown to bind directly to many members of the MAPK kinase superfamily and also to IKK (I $\kappa$ B kinase), preventing signaling through MAP kinases as well as through NF- $\kappa$ B (9).

## Results

**Modification of MEK by YopJ.** In an effort to understand the biochemical basis of the effects of YopJ on cellular signal transduction, we examined MAP kinase signaling in cultured mammalian cells. The Erk MAP kinase cascade is a three-component cascade in which the MAP kinases, Erk1/2, are activated upon phosphorylation by the MAP kinase kinases, MEK1/2, which are in turn, activated upon phosphorylation by the MAP kinase kinase kinase, Raf (Fig. 1*a*). HeLa cells are a well established system for the study of MAPK signaling and show basal nonphosphorylated Erk1/2 and MEK1/2 levels after serum starvation. Treatment of cells with EGF, phorbol ester (TPA), or the  $\beta_2$  adrenergic receptor agonist isoproterenol (ISO) leads to transient activation of the MAPK cascade. Treatment with 10  $\mu$ M ISO at 37°C causes an activation of Erk and MEK within 5 min with a return to basal unphosphorylated levels by 30 min (see Fig. 4, which is published as supporting information on the PNAS web site). Treatment with EGF and TPA also gave rise to robust activation of Erk1/2 and MEK1/2; however, the return to baseline levels was not complete even 60 min after stimulation (see Fig. 4). It was thus decided to use ISO activation for experiments involving a time-course of MAPK activation.

YopJ has previously been shown to interact with MEK2 and to inhibit its activation (9). We examined the effect of YopJ on MAPK signaling by expressing either WT YopJ or the inactive C172A mutant of YopJ in HeLa cells. MEK1/2 activation after ISO stimulation was inhibited in cells expressing WT YopJ (Fig. 1*b*), whereas cells expressing the inactive C172A mutant of YopJ showed the expected activation of MEK1/2 within 5 min of agonist stimulation, with a return to basal unphosphorylated levels by 30 min. Curiously, when the same cell lysates were examined (Fig. 1*b* Lower) for total MEK1/2 protein levels by using a MEK1/2 antibody (CST9122), no signal was detected in cells expressing WT YopJ, whereas cells expressing the C172A mutant of YopJ showed robust signals for total MEK1/2 protein. This effect of YopJ on the immunodetection of total protein levels was specific for MEK1/2 because total amounts of Erk1/2

Author contributions: R.M. and H.T.M. designed research; and R.M. and S.-Y.P.-C. performed research.

The authors declare no conflict of interest.


Freely available online through the PNAS open access option.

Abbreviations: ISO, isoproterenol; amu, atomic mass unit; I $\kappa$ B, inhibitor of NF- $\kappa$ B; IKK, I $\kappa$ B kinase; MEK1/2, mitogen-activated protein kinase kinase 1/2; Yop, *Yersinia* outer protein.

<sup>§</sup>To whom correspondence should be addressed. E-mail: rohit@mrc-lmb.cam.ac.uk.

© 2006 by The National Academy of Sciences of the USA





**Fig. 2.** YopJ modifies MEK2 by acetylation. (a) Before mass spectrometric analysis, myc-MEK2-(His)<sub>6</sub> prepared from YopJ-coexpressing cells (+) and control cells (–) was blotted against different antibodies to ensure it was modified. (b and c) Mass spectrometric analysis of a peptide from MEK2 spanning amino acid residues 210–231. The fragmentation of the modified peptide is shown in b and for the unmodified peptide in c. It can be seen that, whereas Cys-211 is carbamidomethylated (CAM) in each case, Ser-222 and Ser-226 are O-acetylated (OAc) only in YopJ-coexpressing cells. (d) GST-MEK2 (0.5 μg) is acetylated *in vitro* by YopJ-wt in the presence of [<sup>14</sup>C]acetyl coenzymeA. Increasing amounts of YopJ lead to higher acetyl transfer. (e) Time course of acetylation of GST-MEK2 (0.5 μg) by YopJ (80 ng). Progressively greater acetyl transfer is seen over time. The inactive C172A mutant of YopJ does not show any activity in these assays.

charged ion from the YopJ-expressing cells had an *m/z* ratio of 820.1, with an additional mass of 84 atomic mass units (amu) (consistent with the addition of two acetyl groups). Peaks within the fragmentation series of the modified peptide (*m/z* 820.1) were compared with the unmodified one (*m/z* 792.0). The y6 and y10 ions of the modified peptide (Fig. 2b) have masses that are, respectively, 42 amu and 84 amu greater than the corresponding ions in the unmodified peptide (Fig. 2c). This result indicates the addition of acetyl groups on the serine residues at amino acid positions 222 and 226 of MEK2. Subsequent ions in the series y7 to y9 showed a mass increase of 42 amu, and in y11 to y12 an increase of 84 amu, supporting the assignment of these acetylation sites. This finding provides a mechanistic explanation for the ability of YopJ to inhibit activation of MEK as Ser-222 and Ser-226 lie in the activation loop of MEK2 and normally undergo phosphorylation by an upstream kinase to be activated. Prior acetylation of the hydroxyl groups of these serine residues leaves them incapable of accepting phosphates, thereby not permitting MEK2 activation.


Additionally, it was observed that Thr-13 of MEK2 is also a target for O-acetylation by YopJ (see Fig. 5, which is published as supporting information on the PNAS web site). The functional consequence of the acetylation of Thr-13 on MEK2 is currently uncertain. We expect that this acetylation event does not have a large impact on MEK activity because signaling by a constitutively active mutant of the closely related MAP kinase kinase MEK1 (made by replacing the activation loop serines with acidic residues) was not inhibited by expression of YopJ (9).

**YopJ has Acetyltransferase Activity.** YopJ could either be an acetyl transferase by itself or act as an adaptor between MEK2 and some endogenous enzyme. We next examined whether acetyl transferase activity was an inherent property of YopJ. Recombinant

MEK2 expressed as a GST-fusion protein was purified from *Escherichia coli* as were hexahistidine-tagged YopJ-wt and YopJ-C172A. Acetyl transferase activity of WT YopJ is shown in Fig. 2d where it can be seen that progressively higher amounts of YopJ result in greater acetylation of GST-MEK2 in the presence of [<sup>14</sup>C]-labeled acetyl CoA (where the radiolabel is on the acetyl group). Control experiments were performed to verify that GST was not a substrate for acetyl transfer under our assay conditions. Fig. 2e shows a time course of the acetylation reaction over 40 min of incubation of YopJ with MEK2 at 30°C. It is to be noted that in addition to acetyl transfer to MEK2, attachment of the radiolabel to WT YopJ is also seen. The C172A mutant of YopJ does not serve as an acceptor of the acetyl group and thus does not transfer it to the substrate MEK2. These results demonstrate that acetyl transferase activity is an inherent enzymatic property of YopJ.

**YopJ Acetylates IKKα and IKKβ.** In addition to its effect on MAPK signaling, YopJ is also known to exert an inhibitory effect on NF-κB signaling (11). NF-κB is a collective designation for a family of dimeric transcription factors. In resting cells NF-κB is complexed with its inhibitor IκB and retained in the cytoplasm. IκB can be phosphorylated by IκB kinase, IKK (Fig. 3a). Phosphorylation of IκB leads to its ubiquitination and subsequent degradation. NF-κB is then freed to enter the nucleus and affect transcription. IKK is a multisubunit complex comprising two structurally similar catalytic subunits (IKKα and IKKβ) and a variable number of associated regulatory gamma subunits. The canonical pathway of NF-κB activation relies on activation of IKKβ which has been shown to phosphorylate IκB proteins. The kinase activity of IKKα, on the other hand, is required in the so called noncanonical pathway of NF-κB activation that operates mainly in B cells (12, 13). IKKα and IKKβ are highly homologous proteins (52% sequence identity, >70% sequence similarity)





**Fig. 3.** YopJ modifies IKK $\alpha$  and IKK $\beta$ . (a) Various proinflammatory stimuli activate the NF- $\kappa$ B-signaling pathway by activating the I $\kappa$ B kinase (IKK) complex. IKK activation results in the phosphorylation and subsequent ubiquitin-mediated degradation of I $\kappa$ B, the inhibitor of NF- $\kappa$ B. The removal of I $\kappa$ B results in NF- $\kappa$ B translocation to the nucleus where it can regulate gene expression. (b) HEK293 cells transfected with YopJ-wt or YopJ-C172A were stimulated with TNF- $\alpha$ . I $\kappa$ B degradation is slowed down (*Top*) by the expression of YopJ-wt (but not the C172A inactive mutant of YopJ). This effect is due to reduced phosphorylation of I $\kappa$ B in these cells (*Middle*) caused by inhibition of activation of IKK (*Bottom*) caused by WT YopJ. (c and d) Overexpression of IKK $\alpha$  (c) or IKK $\beta$  (d) results in their activation in cells expressing inactive YopJ-C172A but this activation is blocked by WT YopJ (*Upper*). Total levels of IKK $\alpha$  and IKK $\beta$  are not affected by expression of YopJ (*Lower*).

(14) and can be considered to be MAPKK-like molecules in that they are activated by MAPKKK-like molecules (15) and by the fact that the activation loops of MAPKK, IKK $\alpha$ , and IKK $\beta$  all contain two serine residues (or one serine and one threonine residue) within the sequence SxxxS/T that are phosphorylated by upstream kinases (14). Furthermore, a direct interaction of MAPKKs and IKK $\beta$  with YopJ has been reported (9).

We investigated the effect of YopJ expression on the NF- $\kappa$ B pathway by examining the response of YopJ-transfected mammalian cells to the proinflammatory cytokine TNF- $\alpha$ . TNF- $\alpha$  treatment induces a rapid activation of IKK which in turn phosphorylates I $\kappa$ B leading to the ubiquitination and proteasome-mediated degradation of I $\kappa$ B. Fig. 3*b* shows that expression of YopJ results in a reduction in this response when HEK293 cells are exposed to TNF- $\alpha$ . Phosphorylation and degradation of I $\kappa$ B are markedly retarded in cells expressing WT YopJ when compared with cells expressing the inactive C172A mutant of YopJ, which, in turn, correlates well with delayed activation (by phosphorylation) of IKK in these cells (Fig. 3*b Bottom*). These results demonstrate that YopJ affects the activation of IKK in mammalian cells.

Overexpression of either IKK $\alpha$  or IKK $\beta$  is known to result in autophosphorylation of their activation loops leading to activation of their kinase activities (16, 17). We coexpressed Flag-tagged IKK $\alpha$  or Flag-tagged IKK $\beta$  along with YopJ in mammalian cells. These cells were then examined for their response to stimulation with TNF- $\alpha$  (see Fig. 6, which is published as supporting information on the PNAS web site). It was observed that total levels of I $\kappa$ B protein were lower in IKK $\beta$  plus YopJ-wt cells compared with IKK $\beta$  plus YopJ-C172A cells, whereas no such diminution in I $\kappa$ B levels was seen in cells overexpressing IKK $\alpha$  (see Fig. 6 *Upper*). This observation is consistent with the fact that activation of IKK $\beta$  and not IKK $\alpha$  is required for I $\kappa$ B degradation (12). Furthermore, it suggests that WT YopJ “protects” I $\kappa$ B from degradation (presumably by affecting IKK activity), whereas inactive YopJ does not. Fig. 3 *c* and *d Upper* shows that IKK $\alpha$  and IKK $\beta$  are fully autophosphorylated and activated in cells coexpressing inactive YopJ. Activation of these cells with TNF- $\alpha$  does not lead to any detectable increase in the amount of phosphorylated IKK $\alpha$  or IKK $\beta$ . Interestingly it is observed (on these same panels) that recognition of expressed IKK $\alpha$  and IKK $\beta$  by the phospho-specific antibody is abrogated in cells expressing WT YopJ. As control, the total amounts of IKK $\alpha$  and IKK $\beta$  proteins were verified to be the same in cells expressing either form of YopJ (Fig. 3 *c* and *d Lower*). This observation immediately suggests that YopJ modifies IKK $\alpha$  and IKK $\beta$  within the activation loop, most probably by acetylating one or more serine/threonine residues within it.

To identify the site(s) of modification we immunoprecipitated Flag-tagged IKK $\alpha$  and Flag-tagged IKK $\beta$  from cells coexpressing YopJ. Mass spectrometric analysis (see Fig. 7, which is published as supporting information on the PNAS web site) revealed that both IKK $\alpha$  and IKK $\beta$  were indeed acetylated on the activation loop. In each case, the modification was on a threonine residue (indicated in bold) located between the two (underlined) phospho-acceptor serine residues (AKDVDQGS**LC**(OAc)**T**<sup>179</sup>SF in IKK $\alpha$  and AKELDQGS**LC**(OAc)**T**<sup>180</sup>SF in IKK $\beta$ ). In addition to Thr-179, IKK $\alpha$  was also found to be acetylated on Ser-119 in the kinase domain and on Thr-722 located near the carboxyl terminus of IKK $\alpha$ . These two residues are, however, not conserved in IKK $\beta$  and the significance of their modification is not presently clear.

The cysteine residue adjacent to the acetyl-acceptor threonine residue in the activation loops of the catalytic IKK $\alpha$  and IKK $\beta$  subunits has previously been reported to be covalently modified by cyclopentenone prostaglandins (18) and other thiol-reactive agents (19, 20) resulting in the inhibition of IKK activation.

YopJ-mediated acetylation of the activation loop of the  $\alpha$  and  $\beta$  subunits of IKK also prevents activation of the kinase activity of the IKK complex thus preventing phosphorylation of I $\kappa$ B in response to exposure of cells to TNF- $\alpha$ . These results are consistent with an earlier report (21) wherein it was demonstrated that phosphorylation of the activation loop of IKK $\beta$  was inhibited in YopJ-expressing mammalian cells. Our results thus provide a mechanistic basis for the observed inhibition of the canonical NF- $\kappa$ B proinflammatory pathway by YopJ.

Taken together, our results establish that YopJ is an acetyl transferase that catalyses O-acetylation of serine and threonine residues in two important kinases involved in the innate immune response of mammals, thereby inhibiting their activities.

## Discussion

Interestingly, the YopJ-like molecule from *Salmonella typhimurium*, AvrA, has been reported to inhibit the NF- $\kappa$ B pathway (22) and also to inhibit the degradation of  $\beta$ -catenin (23). Phosphorylation of  $\beta$ -catenin occurs within a motif that is highly similar to the phosphorylation motif of I $\kappa$ B (14) and it has been suggested that IKK $\alpha$  may phosphorylate and regulate the deg-

radation of  $\beta$ -catenin (24). It is thus possible that YopJ-related AvrA may also possess an acetyl transferase activity allowing it to inactivate IKK $\alpha$  thereby exerting its effect on  $\beta$ -catenin degradation.

Whereas acetylation of lysine residues in histones and transcription factors has been widely described there have also been reports of regulated acetylation of nonnuclear proteins (25). Furthermore, it has been suggested that acetylation events may temporally modulate IKK activity (26). Our elucidation of the mechanism of action of the bacterial toxin YopJ proposes the hypothesis that serine/threonine acetylation may be a widespread mode of biochemical regulation of endogenous processes in mammalian cells.

The analgesic and antiinflammatory effects of acetyl salicylic acid (Aspirin) administration are attributed to the transfer of the acetyl group to active site serine residues of cyclooxygenase enzymes resulting in the inhibition of their enzymatic activities. However, the cellular enzymes that (possibly) mediate the acetyl transfer have not been identified. Interestingly, there are by now numerous reports of cyclooxygenase-independent actions of acetyl salicylic acid that impinge primarily upon MAP kinase- and NF- $\kappa$ B-signaling pathways (27, 28). In the light of our results, we speculate that some of these effects might be due to the transfer of acetyl groups to the active sites of MAPKKs/IKKs catalyzed by yet uncharacterized serine/threonine acetyl transferases.

## Materials and Methods

**Reagents.** Isoproterenol and EGF were from Sigma (Dorset, U.K.), TPA was from Cell Signaling Technology (Danvers, MA), TNF- $\alpha$  was from R & D Systems (Minneapolis, MN). Primary antibodies against Erk, phosphoErk, MEK1/2, phosphoMEK1/2, MEK1, MEK2, MKK3, MKK4, I $\kappa$ B, phosphoI $\kappa$ B, IKK $\alpha$ , IKK $\beta$ , and phosphoIKK $\alpha/\beta$  were from Cell Signaling Technology; primary antibodies against calnexin were from Affinity BioReagents (Golden, CO); and primary antibodies against  $\beta$ -actin were from Abcam (Cambridge, U.K.).

**Plasmid Constructs.** Plasmids encoding WT YopJ (pSFV-YopJ) and the inactive C172A mutant (pSFV-YopJ-CA) were the kind gifts of K. Orth (University of Texas Southwestern Medical Center, Dallas, TX); pCMV-MEK2 was provided by K.-L. Guan (University of Michigan, Ann Arbor, MI); and pCDNA3-Flag-IKK $\alpha$  and pCMV-Flag-IKK $\beta$  were kindly provided by D. Ballard (Vanderbilt University Medical Center, Nashville, TN).

pCMV-myc-MEK2-(His) $_6$  coding for MEK2 with a hexahistidine tag at its carboxyl terminus was constructed by amplifying the MEK2 sequence with appropriate primers and ligating into pCMV-myc (a modified pCMV5 plasmid). GST-MEK2 was made by amplifying the coding region of MEK2 and ligating in-frame with GST in the bacterial expression plasmid pGEX6P. (His) $_6$ -YopJ-wt and (His) $_6$ -YopJ-C172A were made by ligating the coding region of YopJ in-frame with the amino-terminal hexahistidine tag of the bacterial expression vector pET28. All constructs used were verified by plasmid sequencing.

**Cell Culture and Transfections.** HeLa and HEK293 cells were cultured in DMEM (Invitrogen) with 10% FBS. Transfections were typically done with GeneJuice (Novagen) in 35-mm dishes by using 1  $\mu$ g of plasmid DNA per dish. Twenty-four hours after transfection, cells were serum-starved for 12–16 h and then stimulated with either ISO (10  $\mu$ M) or TNF- $\alpha$  (20 ng/ml) for different times. Cells were harvested in Laemmli Sample Buffer, and lysates were resolved by NuPAGE 4–12% Bis-Tris Gels (Invitrogen). Western Blots were probed with

primary antibodies at a typical dilution of 1:10,000 (except 1:500 for the phosphoIKK $\alpha/\beta$  antibody) at 4°C for 16 h and then incubated with horseradish peroxidase-linked secondary antibodies at room temperature for an hour followed by ECL (Amersham) detection on Kodak BioMax XAR film.

## Mass Spectrometry.

**Identification of modification on MEK2.** Ten micrograms of the pCMV-myc-MEK2-(His) $_6$  construct was transfected either alone or along with 5  $\mu$ g of pSFV-YopJ-wt into each of three 10-cm dishes by using GeneJuice (Novagen). Forty-eight hours after transfection, cells were harvested, and hexahistidine-tagged MEK2 was purified by using NiNTA affinity chromatography. The modified and unmodified MEK2 preparations were resolved by SDS/PAGE and the gel stained by Coomassie blue. Gel slices containing bands corresponding to MEK2 were excised and washed, alkylated, and in-gel digested with trypsin (29). A portion of the extracted tryptic peptides mixture was desalted and concentrated by using a GELoader tip filled with Poros R2 sorbent (Perseptive Biosystems, Framingham, MA). The bound peptides were eluted with 1  $\mu$ l of 60% acetonitrile/3% formic acid directly into a nanospray capillary and then introduced into an API QSTAR pulsar i hybrid quadrupole-time-of-flight mass spectrometer (MDS Sciex, Ontario, Canada). Product ion scans were carried out in positive ion-mode and MS survey scan for peptides from  $m/z$  600 to 1,500 were measured. Selected ions were fragmented by collision-induced dissociation (CID) with nitrogen in the collision cell and spectra of fragment ions produced were recorded in the time-of-flight mass analyzer.

**Identification of modification on IKK $\alpha$  and IKK $\beta$ .** Five micrograms of plasmid encoding Flag-tagged IKK $\alpha$  were cotransfected along with 5  $\mu$ g of either pSFV-YopJ-wt or pSFV-YopJ-C172A into each of three 10-cm tissue culture dishes. Forty-eight hours after transfection, cells were harvested, and Flag-tagged IKK $\alpha$  protein was immunoprecipitated by using EZview Red Anti-Flag M2 affinity gel (Sigma). Immunoprecipitates were resolved on NuPAGE 4–12% Bis-Tris Gels (Invitrogen). Protein bands corresponding to modified and unmodified IKK $\alpha$  were excised from a Coomassie blue-stained gel, washed, alkylated, and in-gel digested with chymotrypsin.

Peptides from the in-gel digest mixtures were separated by nanoscale liquid chromatography (LC Packings, Amsterdam, The Netherlands) on a reverse-phase C18 column (150  $\times$  0.075 mm i.d., flow rate 0.15  $\mu$ l/min). The eluate was introduced directly into a Q-STAR hybrid tandem mass spectrometer (LC-MS/MS). The spectra were searched against a NCBI nonredundant database with MASCOT MS/MS Ions search (www.matrixscience.com). The modified peptides and acetylation sites were identified by manual inspection of the fragmentation series. The same procedure was used with transfected Flag-IKK $\beta$  (in place of IKK $\alpha$ ) to identify the site of modification in IKK $\beta$ .

**Acetyl Transferase Assays.** GST-MEK2 (0.5  $\mu$ g) (purified by using standard protocols for GST-tagged protein purification) was incubated with varying amounts (0–200 ng) of (His) $_6$ -YopJ-wt or (His) $_6$ -YopJ-C172A and 80  $\mu$ M [ $^{14}$ C]acetyl coenzymeA (56 mCi/mmol; Amersham) (1 Ci = 37 GBq) at 30°C for 40 min. Reaction products were resolved on 4–12% SDS/PAGE gels. Gels were stained with Coomassie blue, destained, soaked in Amplify (Amersham) for 30 min, dried, and subjected to autoradiography for 72 h. For time-course experiments, 0.5  $\mu$ g of GST-MEK2 was incubated with 80 ng of (His) $_6$ -YopJ-wt or (His) $_6$ -YopJ-C172A and 80  $\mu$ M [ $^{14}$ C]acetyl coenzymeA at 30°C for varying lengths of time. Reactions were stopped by the


addition of SDS/PAGE sample buffer and analyzed as described above.

**Note.** While this study was being completed, Mukherjee *et al.* (30) reported that YopJ acetylates MKK6 in the activation loop in a manner similar to that reported in this study. Our results confirm that YopJ has acetyl transferase activity, and, taken together, our studies show that, in mammalian cells, this activity inhibits the MAP kinase- and NF- $\kappa$ B-

signaling pathways by targeting the activation loops of MAP kinase kinases (MKKs) and IKKs.


R.M. thanks Sarada Raghavan, JyotiRanjan Mishra, S. Raghavi, and Veronica Rodrigues for help and cooperation. R.M. acknowledges grants from the British Council, India, and from The Royal Society (International Incoming Fellowship) and is currently supported by the Medical Research Council, U.K. (Career Development Fellowship).

1. Galan JE, Cossart P (2005) *Curr Opin Microbiol* 8:1–3.
2. Aktories K, Barbieri JT (2005) *Nat Rev Microbiol* 3:397–410.
3. Cornelis GR (2000) *Proc Natl Acad Sci USA* 97:8778–8783.
4. Galan JE, Collmer A (1999) *Science* 284:1322–1328.
5. Viboud GI, Bliska JB (2005) *Annu Rev Microbiol* 59:69–89.
6. McDonald C, Vacratsis PO, Bliska JB, Dixon JE (2003) *J Biol Chem* 278:18514–18523.
7. Monack DM, Mecsas J, Ghori N, Falkow S (1997) *Proc Natl Acad Sci USA* 94:10385–10390.
8. Zhang Y, Ting AT, Marcu KB, Bliska JB (2005) *J Immunol* 174:7939–7949.
9. Orth K, Palmer LE, Bao ZQ, Stewart S, Rudolph AE, Bliska JB, Dixon JE (1999) *Science* 285:1920–1923.
10. Orth K, Xu Z, Mudgett MB, Bao ZQ, Palmer LE, Bliska JB, Mangel WF, Staskawicz B, Dixon JE (2000) *Science* 290:1594–1597.
11. Schesser K, Spiik AK, Dukuzumuremyi JM, Neurath MF, Pettersson S, Wolf-Watz H (1998) *Mol Microbiol* 28:1067–1079.
12. Chen ZJ (2005) *Nat Cell Biol* 7:758–765.
13. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, et al. (2001) *Science* 293:1495–1499.
14. Karin M, Ben-Neriah Y (2000) *Annu Rev Immunol* 18:621–663.
15. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ (2001) *Nature* 412:346–351.
16. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M (1997) *Cell* 91:243–252.
17. Zandi E, Chen Y, Karin M (1998) *Science* 281:1360–1363.
18. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santoro MG (2000) *Nature* 403:103–108.
19. Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY, Karin M (2000) *J Biol Chem* 275:36062–36066.
20. Jeon KI, Byun MS, Jue DM (2003) *Exp Mol Med* 35:61–66.
21. Carter RS, Pennington KN, Ungurait BJ, Arrate P, Ballard DW (2003) *J Biol Chem* 278:48903–48906.
22. Collier-Hyams LS, Zeng H, Sun J, Tomlinson AD, Bao ZQ, Chen H, Madara JL, Orth K, Neish AS (2002) *J Immunol* 169:2846–2850.
23. Sun J, Hobert ME, Rao AS, Neish AS, Madara JL (2004) *Am J Physiol Gastrointest Liver Physiol* 287:G220–227.
24. Albanese C, Wu K, D'Amico M, Jarrett C, Joyce D, Hughes J, Hult J, Sakamaki T, Fu M, Ben-Ze'ev A, et al. (2003) *Mol Biol Cell* 14:585–599.
25. Kouzarides T (2000) *EMBO J* 19:1176–1179.
26. Quivy V, Van Lint C (2004) *Biochem Pharmacol* 68:1221–1229.
27. Tegeder I, Pfeilschifter J, Geisslinger G (2001) *FASEB J* 15:2057–2072.
28. Gao Z, Zuberi A, Quon MJ, Dong Z, Ye J (2003) *J Biol Chem* 278:24944–24950.
29. Shevchenko A, Wilm M, Vorm O, Mann M (1996) *Anal Chem* 68:850–858.
30. Mukherjee S, Keitany G, Li Y, Wang Y, Ball HL, Goldsmith EJ, Orth K (2006) *Science* 312:1211–1214.




**Fig. 4.** Stimulation of MEK and Erk phosphorylation by various extracellular stimuli. HeLa cells that had been serum-starved for 16 h were stimulated with either EGF (20 ng/ml), TPA (200 ng/ml), or isoproterenol (10  $\mu$ M) at 37°C, and the activation (by phosphorylation) of MEK and Erk was detected by the use of phospho-specific antibodies. Isoproterenol was chosen as the stimulus for the experiments reported in this article because the rapid activation and decay of the signals allowed us to collect a complete time course.






**Fig. 5.** YopJ acetylates MEK2 on Thr-13. Tryptic digests of MEK2 purified from YopJ-coexpressing cells (+) and control cells (-) were subjected to LC-MS/MS. A mass difference of 42 amu (corresponding to the mass of one acetyl group) was detected in the peptides corresponding to aa5-aa39. Collision-induced fragmentation of these peptides is depicted here. Both peptides display the same y-ion series (up to y13, although data only up to y6 is shown here) and identical *m/z* ratios for the b-series ion, b8. The difference between the b9 (and subsequent) ions in the two preparations indicates that the threonine residue at position 13 in MEK2 is O-acetylated by YopJ.





**Fig. 6.** YopJ protects I $\kappa$ B from degradation in IKK $\beta$  -overexpressing cells by modifying IKK. HEK293 cells were cotransfected with IKK $\alpha$  and either YopJ-wt or YopJ-C172A (*Left*). Similarly, they were cotransfected with IKK $\beta$  and either YopJ-wt or YopJ-C172A (*Right*). Twenty-four hours after transfection, cells were serum-starved for 16 h and then stimulated with 20 ng/ml TNF- $\alpha$ . At the indicated time points, cells were harvested and processed for Western blotting. The boxed regions in the *Upper* panel of anti-I $\kappa$ B blots show that the resting amount of I $\kappa$ B is much lower in cells overexpressing IKK $\beta$  and inactive YopJ compared with those expressing IKK $\beta$  and active YopJ. This result is owing to the fact that (even in the absence of TNF- $\alpha$  stimulation) overexpressed IKK $\beta$  autoactivates and phosphorylates I $\kappa$ B, leading to its ubiquitination and degradation by the proteasome. This results in the reduced resting levels of I $\kappa$ B seen in YopJ-C172A coexpressing cells. Coexpressed WT YopJ, however, modifies IKK $\beta$ , inhibiting its ability to phosphorylate I $\kappa$ B, thus resulting in higher resting levels of I $\kappa$ B. This interpretation is reinforced by the phosphoI $\kappa$ B blot that shows elevated levels of high molecular weight polyubiquitinated phospho I $\kappa$ B in the C172A coexpressing cells. Also, the phosphoI $\kappa$ B blot shows that, upon TNF- $\alpha$  treatment, the kinetics of appearance of phosphoI $\kappa$ B is reduced in C172A coexpressing cells (red box), reflecting the lowered amount of I $\kappa$ B present in the cells at the time of TNF- $\alpha$  stimulation. TNF- $\alpha$  treatment results in the complete degradation of I $\kappa$ B, presumably due to phosphorylation by the small percentage of unmodified IKK $\beta$  that would be present in YopJ-wt coexpressing cells. Similar effects are not seen with IKK $\alpha$  overexpressing cells because, even though IKK $\alpha$  autoactivates (see phosphoIKK $\alpha$  blot), its preferred target is not I $\kappa$ B. The *Lower* three panels show that both IKK $\alpha$  and IKK $\beta$  are modified by WT YopJ such that their activation is inhibited, but total protein amounts are unaffected.



**Fig. 7.** YopJ acetylates IKK $\alpha$  on Thr-179. Flag-IKK $\alpha$  was prepared by immunoprecipitation from cells coexpressing either YopJ-wt or the inactive mutant YopJ-C172A. Peptides resulting from chymotrypsin treatment of the preparations were resolved by nanoscale liquid chromatography and analyzed by mass spectrometry. From such an LC-MS/MS experiment, a doubly charged ion at  $m/z$  735.3 corresponding to the amino acid sequence A<sup>169</sup>KDVDQGSLC\*TSF<sup>181</sup> (C\* is carbamidomethylcysteine), with an additional mass of 42 amu (one acetyl group), was detected. This ion was selected and subjected to collision-induced fragmentation. Comparison of the fragmentation data from this modified peptide (*Upper*) with that from the unmodified doubly charged ion at  $m/z$  714.3 (*Lower*) shows that they have the same b-ion series (b2 to -10) and y1 and y2 ions. The difference of 42 amu in y4 ions indicates that the acetylation site is on threonine 179 of IKK $\alpha$ .